We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$561M
Cap. Flow %
15.73%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 0.67%
3 Consumer Discretionary 0.06%
4 Industrials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.6B
$395M 11.06%
4,761,989
-389,600
-8% -$32.9M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$301M 8.44%
20,024,424
+2,135,827
+12% +$32.5M
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$241M 6.75%
4,989,066
+100,000
+2% +$5.58M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$159M 4.45%
3,970,357
– –
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$32.1B
$153M 4.27%
1,280,802
-50,000
-4% -$6.45M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$128M 3.6%
4,313,611
+925,000
+27% +$29.8M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$3.82B
$104M 2.92%
6,162,202
+1,386,088
+29% +$21M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$97.4M 2.73%
+873,450
New +$104M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$96.7M 2.71%
332,449
+117,449
+55% +$29.8M
BPMC
10
DELISTED
Blueprint Medicines
BPMC
$94.5M 2.65%
1,030,434
-110,000
-10% -$9.48M
DOVA
11
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$75.4M 2.11%
2,780,977
+971,962
+54% +$29.1M
CORI
12
DELISTED
Corium International, Inc.
CORI
$72.9M 2.04%
6,357,133
+510,000
+9% +$6.15M
TVTX icon
13
Travere Therapeutics
TVTX
$6.32B
$71.8M 2.01%
3,212,871
+540,346
+20% +$12.9M
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$71.2M 1.99%
2,927,449
+2,666,315
+1,021% +$79.7M
ASND icon
15
Ascendis Pharma A/S
ASND
$16.6B
$64.3M 1.8%
+982,647
New +$55.2M
CTMX icon
16
CytomX Therapeutics
CTMX
$734M
$62.8M 1.76%
2,208,812
-281,569
-11% -$8.04M
YARW
17
Yarrow Bioscience
YARW
$105M
$60.1M 1.68%
+444
New +$54M
XLRN
18
DELISTED
Acceleron Pharma
XLRN
$59.3M 1.66%
1,516,259
-100,000
-6% -$4.25M
ALBO
19
DELISTED
Albireo Pharma Inc
ALBO
$55.5M 1.55%
1,704,330
+384,330
+29% +$12.9M
DBVT
20
DBV Technologies
DBVT
$941M
$48.3M 1.35%
209,350
+111,488
+114% +$26.3M
MMSI icon
21
Merit Medical Systems
MMSI
$5.44B
$47.4M 1.33%
1,045,013
+171,000
+20% +$7.74M
ARGX icon
22
argenx
ARGX
$63.8B
$43.2M 1.21%
537,361
– –
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$40.7M 1.14%
834,679
+123,953
+17% +$6.44M
XNCR icon
24
Xencor
XNCR
$2.18B
$39.5M 1.11%
1,318,095
+5,000
+0.4% +$131K
AVXS
25
DELISTED
AveXis, Inc. Common Stock
AVXS
$34.2M 0.96%
276,400
-203,741
-42% -$24.2M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.